TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cardiol Therapeutics ( (TSE:CRDL) ) has provided an update.
On December 1, 2025, Cardiol Therapeutics announced new data from its Phase II ARCHER trial, revealing that CardiolRx™ significantly improves heart structure in patients with acute myocarditis. The trial demonstrated a reduction in left ventricular mass and improvements in cardiac MRI measures, supporting the expansion of CardiolRx™ across various inflammatory cardiac conditions. These findings bolster the scientific rationale for Cardiol’s ongoing Phase III MAVERIC trial in recurrent pericarditis and highlight the potential of CardiolRx™ as a novel treatment for inflammatory heart diseases.
The most recent analyst rating on (TSE:CRDL) stock is a Buy with a C$9.00 price target. To see the full list of analyst forecasts on Cardiol Therapeutics stock, see the TSE:CRDL Stock Forecast page.
Spark’s Take on TSE:CRDL Stock
According to Spark, TipRanks’ AI Analyst, TSE:CRDL is a Underperform.
Cardiol Therapeutics faces substantial financial challenges, primarily driven by ongoing losses and negative cash flow. The stock’s technical indicators suggest mixed momentum, and its valuation is constrained by a negative P/E ratio. However, promising clinical developments and strategic advancements in heart disease treatments provide some positive outlook, though these are not sufficient to offset the financial and technical concerns.
To see Spark’s full report on TSE:CRDL stock, click here.
More about Cardiol Therapeutics
Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. The company is advancing its lead product, CardiolRx™, aimed at treating inflammatory cardiac conditions, with a particular focus on heart failure and myocarditis.
YTD Price Performance: -23.35%
Average Trading Volume: 129,153
Technical Sentiment Signal: Sell
Current Market Cap: C$151M
For an in-depth examination of CRDL stock, go to TipRanks’ Overview page.